Edition:
United Kingdom

Otsuka Holdings Co Ltd (4578.T)

4578.T on Tokyo Stock Exchange

5,302JPY
20 Apr 2018
Change (% chg)

¥-35 (-0.66%)
Prev Close
¥5,337
Open
¥5,333
Day's High
¥5,352
Day's Low
¥5,293
Volume
924,500
Avg. Vol
1,149,280
52-wk High
¥5,568
52-wk Low
¥4,290

Chart for

About

Otsuka Holdings Co., Ltd. is a Japan-based company engaged in medical, nutraceuticals related, consumer related and other business segments. The Medical-related segment is engaged in the sale of ethical drugs, the manufacture, sale and export of curative medicines, as well as the research and development of infusions. The... (more)

Overall

Beta: 0.44
Market Cap(Mil.): ¥2,513,607.00
Shares Outstanding(Mil.): 557.84
Dividend: 50.00
Yield (%): 2.22

Financials

  4578.T Industry Sector
P/E (TTM): 28.71 30.95 32.74
EPS (TTM): 156.94 -- --
ROI: 4.42 14.84 14.38
ROE: 5.21 16.34 16.07

BRIEF-Otsuka Pharmaceutical Says Co, X-Chem Have Signed Collaborative Research Agreement To Advance Discovery Process For New Otsuka Drug Compounds

* OTSUKA PHARMACEUTICAL SAYS CO, X-CHEM INC HAVE SIGNED COLLABORATIVE RESEARCH AGREEMENT TO ADVANCE DISCOVERY PROCESS FOR NEW OTSUKA DRUG COMPOUNDS Source text for Eikon: Further company coverage:

19 Dec 2017

BRIEF-Otsuka Holdings to transfer medical device business to unit

* Says co plans to transfer medical device business to co's wholly owned unit Otsuka Medical Devices Co Ltd, with effective date of Jan. 1, 2018

14 Nov 2017

BRIEF-FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

* FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

09 Nov 2017

BRIEF-Otsuka Canada Pharmaceutical says Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​

* Otsuka Canada Pharmaceutical Inc-Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​ Source text for Eikon: Further company coverage:

02 Nov 2017

BRIEF-Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type

* Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018

01 Nov 2017

Earnings vs. Estimates